PRELUDE THERAPEUTICS INC Investing Cash Flow
PRELUDE THERAPEUTICS INC (PRLD) reported Investing Cash Flow of -$57.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$65.50M, a 668.55% decline year-over-year.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $8.50M, a 86.33% decline year-over-year.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$60.34M, a 372.80% decline year-over-year.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $40.09M, a 273.53% increase year-over-year.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for fiscal 2025 was $53.46M, a 40.73% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for fiscal 2024 was $90.19M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for fiscal 2023 was -$34.65M, a 142.41% decline from fiscal 2022.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) investing activities for fiscal 2022 was $81.69M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$65.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$57.00M 10-Q · filed 2026-08-11 | -$117.34M derived: sum of 3 quarters · filed 2026-08-11 | -$77.25M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $8.50M 10-Q · filed 2026-05-12 | -$51.84M derived: sum of 2 quarters · filed 2026-05-12 | -$11.75M derived: sum of 3 quarters · filed 2026-05-12 | -$228.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$60.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$20.25M derived: sum of 2 quarters · filed 2026-03-10 | -$8.73M derived: sum of 3 quarters · filed 2026-08-11 | $53.46M 10-K · filed 2026-03-10 | |
| 2025-09-30 | $40.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $51.61M derived: sum of 2 quarters · filed 2026-08-11 | $113.80M 10-Q · filed 2025-11-12 | $135.92M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $11.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $73.71M 10-Q · filed 2026-08-11 | $95.83M derived: sum of 3 quarters · filed 2026-08-11 | $106.56M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $62.19M 10-Q · filed 2026-05-12 | $84.30M derived: sum of 2 quarters · filed 2026-05-12 | $95.04M derived: sum of 3 quarters · filed 2026-05-12 | $121.16M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $22.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $32.85M derived: sum of 2 quarters · filed 2026-03-10 | $58.97M derived: sum of 3 quarters · filed 2026-03-10 | $90.19M 10-K · filed 2026-03-10 | |
| 2024-09-30 | $10.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $36.85M derived: sum of 2 quarters · filed 2025-11-12 | $68.07M 10-Q · filed 2025-11-12 | $75.81M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $26.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $57.34M 10-Q · filed 2025-08-14 | $65.08M derived: sum of 3 quarters · filed 2025-08-14 | $80.12M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $31.22M 10-Q · filed 2025-05-06 | $38.96M derived: sum of 2 quarters · filed 2025-05-06 | $54.00M derived: sum of 3 quarters · filed 2025-05-06 | -$21.42M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $22.78M derived: sum of 2 quarters · filed 2025-03-10 | -$52.65M derived: sum of 3 quarters · filed 2025-03-10 | -$34.65M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $15.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$60.38M derived: sum of 2 quarters · filed 2024-11-06 | -$42.38M 10-Q · filed 2024-11-06 | -$41.03M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$75.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$57.43M 10-Q · filed 2024-08-12 | -$56.07M derived: sum of 3 quarters · filed 2024-08-12 | -$34.47M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $18.00M 10-Q · filed 2024-05-07 | $19.35M derived: sum of 2 quarters · filed 2024-05-07 | $40.96M derived: sum of 3 quarters · filed 2024-05-07 | $99.54M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $22.96M derived: sum of 2 quarters · filed 2024-02-15 | $81.54M derived: sum of 3 quarters · filed 2024-02-15 | $81.69M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $21.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $80.18M derived: sum of 2 quarters · filed 2023-11-01 | $80.34M 10-Q · filed 2023-11-01 | $78.53M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | $58.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $58.73M 10-Q · filed 2023-08-03 | $56.92M derived: sum of 3 quarters · filed 2023-08-03 | -$203.71M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $153.00K 10-Q · filed 2023-05-08 | $41.55M 10-Q · filed 2022-05-10 | -$1.65M derived: sum of 2 quarters · filed 2023-05-08 | -$262.28M derived: sum of 3 quarters · filed 2023-05-08 | -$262.66M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$262.44M derived: sum of 2 quarters · filed 2023-03-15 | -$262.82M derived: sum of 3 quarters · filed 2023-03-15 | -$263.80M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$260.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$261.01M derived: sum of 2 quarters · filed 2022-11-14 | -$262.00M 10-Q · filed 2022-11-14 | -$262.33M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$381.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.37M 10-Q · filed 2022-08-09 | -$1.70M derived: sum of 3 quarters · filed 2022-08-09 | -$1.87M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$986.00K 10-Q · filed 2022-05-10 | -$1.31M derived: sum of 2 quarters · filed 2022-05-10 | -$1.49M derived: sum of 3 quarters · filed 2022-05-10 | -$1.53M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$499.00K derived: sum of 2 quarters · filed 2022-03-17 | -$541.00K derived: sum of 3 quarters · filed 2022-03-17 | -$621.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$212.00K derived: sum of 2 quarters · filed 2021-11-12 | -$292.00K 10-Q · filed 2021-11-12 | -$491.00K derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$122.00K 10-Q · filed 2021-08-12 | -$321.00K derived: sum of 3 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$80.00K 10-Q · filed 2021-05-11 | -$279.00K derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | -$199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$780.00K 10-K · filed 2021-03-16 | |||
| 2019-09-30 | -$581.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |